Interim Analysis of a Phase 2 Open‐Label Trial Assessing Burosumab Efficacy and Safety in Patients With Tumor‐Induced Osteomalacia-Reference-Cited by-同舟云学术

Interim Analysis of a Phase 2 Open‐Label Trial Assessing Burosumab Efficacy and Safety in Patients With Tumor‐Induced Osteomalacia

Published:2020-11-04 Issue:2 Volume:36 Page:262-270
ISSN:0884-0431
Container-title:Journal of Bone and Mineral Research
language:en
Short-container-title:J Bone Miner Res

Author:

Imanishi Yasuo¹^ORCID,Ito Nobuaki²,Rhee Yumie³^ORCID,Takeuchi Yasuhiro⁴⁵,Shin Chan Soo⁶,Takahashi Yutaka⁷,Onuma Hiroki⁸,Kojima Masahiro⁸,Kanematsu Masanori⁸,Kanda Hironori⁸,Seino Yoshiki⁹,Fukumoto Seiji¹⁰

Affiliation:

1. Department of Metabolism, Endocrinology, and Molecular Medicine Osaka City University Graduate School of Medicine Osaka Japan

2. Division of Nephrology and Endocrinology The University of Tokyo Hospital Tokyo Japan

3. Department of Internal Medicine, Severance Hospital, Endocrine Research Institute Yonsei University College of Medicine Seoul Republic of Korea

4. Endocrine Center Toranomon Hospital Tokyo Japan

5. Okinaka Memorial Institute for Medical Research Tokyo Japan

6. Department of Internal Medicine Seoul National University Hospital Seoul Republic of Korea

7. Division of Diabetes and Endocrinology Kobe University Hospital Kobe Japan

8. Kyowa Kirin Co., Ltd. Tokyo Japan

9. Department of Pediatrics Osaka Hospital, Japan Community Healthcare Organization (JCHO) Osaka Japan

10. Fujii Memorial Institute of Medical Sciences, Institute of Advanced Medical Sciences Tokushima University Tokushima Japan

Publisher

Wiley

Subject

Orthopedics and Sports Medicine,Endocrinology, Diabetes and Metabolism

Link

https://onlinelibrary.wiley.com/doi/pdf/10.1002/jbmr.4184

Reference27 articles.

1. Cloning and characterization of FGF23 as a causative factor of tumor-induced osteomalacia

2. Tumour-induced osteomalacia

3. FGF23, Hypophosphatemia, and Emerging Treatments

4. Tumor-induced osteomalacia

5. X-Linked Hypophosphatemia and FGF23-Related Hypophosphatemic Diseases: Prospect for New Treatment

Cited by 59 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Healthcare Resource Use Associated With Tumor-Induced Osteomalacia: A Literature Review;The Journal of Clinical Endocrinology & Metabolism;2024-06-24

2. Tumor-induced osteomalacia: A systematic literature review;Bone Reports;2024-06

3. Tumor-Induced Osteomalacia due to Sarcomatoid Non–Small Cell Lung Carcinoma Confounded by Drug-Induced Fanconi Syndrome;JCEM Case Reports;2024-05-24

4. Acquired Forms of Fibroblast Growth Factor 23-Related Hypophosphatemic Osteomalacia;Endocrinology and Metabolism;2024-04-30

5. Preoperative evaluation and orthopedic surgical strategies for tumor-induced osteomalacia;Journal of Bone Oncology;2024-04